Technology Accelerator Domain 2
Product development oversight within MATRIX is provided by MATRIX’s Scientific Advisory Group (SAG). The SAG is composed of US and international scientists with a wide range of expertise who, on a biannual basis, evaluate the progress of MATRIX’s critical path projects. SAG evaluations allow MATRIX to actively monitor critical path project progress and make recommendations to continue product development (proceed), address experimental delays and correct problems or barriers to progress (mitigation) or determine that no further progress can be made or that the product is no longer of interest to MATRIX and USAID (stop). For projects placed in mitigation, progress on problem resolution is monitored by the SAG and recommendations to continue mitigation efforts, stop development, or return to the critical path can be made. The SAG process also allows MATRIX to take advantage of new product development opportunities by on-boarding new projects. Thus, the SAG-driven product development oversight acts as the main engine for critical path product development and oversight within MATRIX and is designed to move products from initial development to investigational new drug (IND)-enabling studies, first-in-human clinical trials, and late-stage development, while taking advantage of new opportunities in the HIV prevention and dual-prevention product space.
Key contacts